3D Medicines, Inc. is an investing holding company, which focuses on the development and commercialization of immuno-oncology (I/O) therapies with differentiated clinical benefit in response to the trend of treating cancer as a chronic disease. The company was founded by Zhao Long Gong in 2014 and is headquartered in Shanghai, China.